for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Moderna Inc

MRNA.OQ

Latest Trade

164.25USD

Change

3.75(+2.34%)

Volume

1,728,338

Today's Range

160.85

 - 

169.00

52 Week Range

46.14

 - 

189.26

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
160.50
Open
165.78
Volume
1,728,338
3M AVG Volume
204.48
Today's High
169.00
Today's Low
160.85
52 Week High
189.26
52 Week Low
46.14
Shares Out (MIL)
400.18
Market Cap (MIL)
65,165.30
Forward P/E
7.46
Dividend (Yield %)
--

Next Event

Moderna Inc Science Day

Latest Developments

More

Moderna Reports Qtrly EPS Of $2.84

Moderna Expands Manufacturing Technology Center In Massachusetts

Moderna Announces Emergency Use Listing Granted By WHO For Its Covid-19 Vaccine

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Moderna Inc

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Industry

Biotechnology & Drugs

Contact Info

200 Technology Sq

Cambridge, MA

02139-3578

United States

+1.617.7146500

https://www.modernatx.com/

Executive Leadership

Noubar B. Afeyan

Non-Executive Independent Chairman of the Board, Co-Founder

Stephen Hoge

President

Stephane Bancel

Chief Executive Officer, Director

David W. Meline

Chief Financial Officer

Tracey Franklin

Chief Human Resources Officer

Key Stats

2.56 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.8K

2021(E)

17.4K
EPS (USD)

2018

-4.950

2019

-1.550

2020

-1.960

2021(E)

23.269
Price To Earnings (TTM)
--
Price To Sales (TTM)
81.11
Price To Book (MRQ)
25.35
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
5.24
LT Debt To Equity (MRQ)
4.29
Return on Investment (TTM)
-34.00
Return on Equity (TTM)
-16.74

Latest News

Latest News

Unused COVID shots piling up in Japan amid slow rollout

Unused COVID-19 vaccines in Japan are set to reach tens of millions of doses, as the country is poised to approve two more shots in coming weeks and the pace of its inoculation campaign remains slow due to manpower and logistical bottlenecks.

Japan may approve AstraZeneca, Moderna vaccines as early as May 20 - Nikkei

Japan's government may approve the use of coronavirus vaccines developed by AstraZeneca PLC and Moderna Inc as early as May 20, the Nikkei reported on Friday.

Moderna sees no impact on COVID-19 vaccine from potential patent waiver

Moderna Inc on Thursday said it believes countries around the globe would continue buying its COVID-19 vaccine for years even if patents on the shots are waived, noting that rivals would face significant hurdles in scaling up manufacturing.

Moderna says waiving IP rights won't help increase vaccine supply

Moderna Inc said on Thursday that waiving intellectual property rights on COVID-19 vaccines will not help boost supply in 2021 or 2022, a day after U.S. President Joe Biden backed a proposed waiver that is aimed at giving poorer companies access.

Moderna raises 2021 sales forecast for COVID-19 vaccine to $19.2 bln

Moderna Inc raised its 2021 sales forecast for its COVID-19 vaccine by 4.3% to $19.2 billion on Thursday, reflecting demand from countries looking to return to normalcy through rapid inoculation.

Moderna booster increases antibodies against COVID-19 variants, early data shows

Moderna Inc said on Wednesday early human trial data shows that a third dose of either its current COVID-19 shot or an experimental new vaccine candidate increases immunity against variants of COVID-19 first found in Brazil and South Africa.

Moderna booster increases antibodies against COVID-19 variants, early data shows

Moderna Inc said on Wednesday early human trial data shows that a third dose of either its current COVID-19 shot or an experimental new vaccine candidate increases immunity against variants of COVID-19 first found in Brazil and South Africa.

Philippines approves emergency use of Moderna's COVID-19 vaccine

The Philippines' food and drug agency approved on Wednesday the emergency use of U.S. drugmaker Moderna Inc's COVID-19 vaccine in the Southeast Asian nation.

Moderna deal, Swedish donation boost COVAX vaccine-sharing platform

Moderna will supply 34 million doses of its COVID-19 vaccine this year and Sweden has donated 1 million AstraZeneca shots to the global COVAX programme as it struggles to secure enough supplies to inoculate the world's poorest people.

COVAX gets boost from Moderna deal, Sweden's donation of COVID-19 vaccines -GAVI

Moderna will supply 34 million doses of its COVID-19 vaccine this year and Sweden has donated 1 million AstraZeneca shots to the global COVAX programme, a small boost as it struggles to get stocks to inoculate the world's poorest people.

Japan to approve Moderna's COVID-19 vaccine as soon as May 21 - Yomiuri

Japanese regulators are set to approve Moderna Inc's COVID-19 vaccine as soon as May 21, the Yomiuri Shimbun newspaper reported Saturday, without citing the source of the information.

WHO gives emergency use listing to Moderna's COVID-19 vaccine

The World Health Organization has listed Moderna's COVID-19 vaccine for emergency use, the agency said on Friday, the fifth to be given the status meant to expedite countries' own approval of shots.

First Moderna COVID-19 vaccines arrive in Japan: NHK

The first delivery of Moderna Inc's COVID-19 vaccines arrived in Japan on Friday, public broadcaster NHK reported, citing airline officials.

Help wanted: Lonza seeks workers to lift Moderna vaccine output

Three Lonza manufacturing lines for Moderna's COVID-19 vaccine are due to reach production capacity by late June, Chief Executive Pierre-Alain Ruffieux said on Thursday, though he still needs about 100 more workers to staff them.

Lonza says 3 Moderna vaccine ingredient lines to be at capacity by end-June

Three new Lonza production lines that manufacture ingredients for Moderna's COVID-19 vaccine are due to be producing at capacity by the end of June, Chief Executive Pierre-Alain Ruffieux said on Thursday in an interview.

Spain's Rovi will double its capacity to bottle Moderna's COVID-19 vaccines

Spanish contract drugmaker Rovi said on Thursday it will double its capacity to bottle COVID-19 vaccines for Moderna.

Moderna boosting COVID-19 vaccine-making capacity, targets up to 3 billion shots in 2022

Moderna Inc said on Thursday it is boosting manufacturing capacity for its COVID-19 vaccine and expects to make up to 3 billion doses in 2022, more than twice its previous forecast.

BRIEF-Moderna Announces Additional Investments To Increase Global Supply For COVID-19 Vaccine To Up To 3 Bln Doses In 2022

* MODERNA INC - ANNOUNCES ADDITIONAL INVESTMENTS TO INCREASE GLOBAL SUPPLY FOR COVID-19 VACCINE TO UP TO 3 BILLION DOSES IN 2022

Switzerland's Lonza to boost production for Moderna COVID-19 vaccine

Contract drug manufacturer Lonza plans to double Swiss production capacity for Moderna's COVID-19 vaccine, helping the U.S. drugmaker boost total output to as many as 3 billion doses in 2022. (Reporting by John Miller Editing by Riham Alkousaa)

U.S. trade negotiator discusses COVID-19 IP waiver with Moderna CEO

U.S. Trade Representative Katherine Tai on Wednesday met virtually with the top executive of drugmaker Moderna to discuss a proposed waiver of certain intellectual property rights in response to the COVID-19 pandemic, Tai's office said.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up